ESPR Esperion Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ESPR

Price (delayed)

$1.46

Market cap

$138.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.39

Enterprise value

$506.59M

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make ...

Highlights
Esperion Therapeutics's EPS has increased by 50% YoY and by 3.7% QoQ
Esperion Therapeutics's debt has decreased by 2.6% YoY
ESPR's revenue is down by 9% year-on-year but it is up by 7% since the previous quarter
The quick ratio has contracted by 44% YoY and by 4.1% from the previous quarter
The equity has decreased by 32% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.esperion.com
Peers: RARE BMRN REGN PFE

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
94.71M
Market cap
$138.28M
Enterprise value
$506.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.26
Earnings
Revenue
$80.97M
EBIT
-$181.51M
EBITDA
-$181.08M
Free cash flow
-$190.19M
Per share
EPS
-$3.39
Free cash flow per share
-$2.42
Book value per share
-$4.31
Revenue per share
$1.03
TBVPS
$3.21
Balance sheet
Total assets
$251.82M
Total liabilities
$581.48M
Debt
$513.22M
Equity
-$329.66M
Working capital
$155.12M
Liquidity
Debt to equity
-1.56
Current ratio
2.62
Quick ratio
2.08
Net debt/EBITDA
-2.03
Margins
EBITDA margin
-223.6%
Gross margin
61.1%
Net margin
-294.7%
Operating margin
-228.6%
Efficiency
Return on assets
-85.5%
Return on equity
N/A
Return on invested capital
-32.8%
Return on capital employed
-116.1%
Return on sales
-224.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
-2.01%
1 week
-10.98%
1 month
20.66%
1 year
-73.5%
YTD
-76.57%
QTD
-8.18%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$80.97M
Gross profit
$49.47M
Operating income
-$185.12M
Net income
-$238.65M
Gross margin
61.1%
Net margin
-294.7%
The company's gross profit fell by 29% YoY
The gross margin has contracted by 22% YoY and by 5% from the previous quarter
Esperion Therapeutics's net margin has decreased by 12% YoY but it has increased by 4.8% QoQ
ESPR's operating margin is down by 9% year-on-year but it is up by 3.9% since the previous quarter

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.26
Esperion Therapeutics's EPS has increased by 50% YoY and by 3.7% QoQ
The equity has decreased by 32% YoY
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 15.9 and 71% lower than the last 4 quarters average of 4.8
ESPR's revenue is down by 9% year-on-year but it is up by 7% since the previous quarter

Efficiency

How efficient is Esperion Therapeutics business performance
The return on assets has declined by 12% year-on-year and by 10% since the previous quarter
Esperion Therapeutics's return on sales has decreased by 10% YoY but it has increased by 4.3% QoQ
The return on invested capital has declined by 5% since the previous quarter but it has grown by 2.7% year-on-year

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 57% less than the total liabilities
The quick ratio has contracted by 44% YoY and by 4.1% from the previous quarter
The company's current ratio fell by 29% YoY
The equity has decreased by 32% YoY
ESPR's debt to equity is up by 26% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.